Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.
Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.
复制标题
DOI：
10.3109/07357907.2014.889706
复制
发表时间：
2014-05
影响因子：
2.4
通讯作者：
Hershman DL
中科院分区：
文献类型：
--
作者：
Kalinsky K;Crew KD;Refice S;Xiao T;Wang A;Feldman SM;Taback B;Ahmad A;Cremers S;Hibshoosh H;Maurer M;Hershman DL
我们进行了一项术前试验，以评估二甲双胍对超重/肥胖乳腺癌（BC）患者的组织相关影响。对35例0-III期BC、体重指数(BMI)≥25kg /m2的非糖尿病患者，每日给予二甲双胍1500mg。主要终点是肿瘤增殖变化（即ki-67）。将肿瘤增殖变化与未治疗的历史对照进行比较，并与年龄、BMI和分期相匹配。与对照组相比，二甲双胍后ln（ki-67）没有降低（p = 0.98）或（p = 0.47）。体重指数、胆固醇和瘦素都有显著降低。尽管没有增殖变化，但我们观察到其他相关生物标志物的减少。
We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients. Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0–III BC, body mass index (BMI) ≥ 25 kg/m2. The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage. There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin. Despite no proliferation changes, we observed reductions in other relevant biomarkers.
登录
查看更多内容
影响因子：
120.7
作者：
Hadigan, C;Corcoran, C;Grinspoon, S
通讯作者：
Grinspoon, S
影响因子：
5.8
作者：
Hasson, Rebecca E.;Adam, Tanja C.;Goran, Michael I.
通讯作者：
Goran, Michael I.
影响因子：
9.8
作者：
Panarotto, D;Ardilouze, JL;Maheux, P
通讯作者：
Maheux, P
影响因子：
45.3
作者：
Jiralerspong, Sao;Palla, Shana L.;Gonzalez-Angulo, Ana M.
通讯作者：
Gonzalez-Angulo, Ana M.
影响因子：
3.8
作者：
Niraula, Saroj;Dowling, Ryan J. O.;Goodwin, Pamela J.
通讯作者：
Goodwin, Pamela J.